A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819)

Trial Information

A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819)

OBJECTIVES: I. Determine the maximum target-inhibiting dose of SU5416 in patients with
advanced solid tumors. II. Determine the relationship between dose or plasma levels and the
clinical safety profile and antitumor effects of this treatment regimen in terms of
objective response, stabilization of disease, or progression-free survival in this patient
population. III. Evaluate the relationship between dose or plasma levels of SU5416
concentrations and the ability of this treatment regimen to reduce microvessel density and
induce apoptosis of endothelial and tumor cells in this patient population. IV. Determine
prognostic and surrogate serologic markers in these patients treated with this regimen. V.
Determine if pre and posttreatment plasma and serum levels of angiogenic growth factors,
basic fibroblast growth factor, and vascular endothelial cell growth factor are prognostic
in predicting patient response to this regimen. VI. Determine if elevated plasma levels of
endothelial cell specific proteins reflective of SU5416-induced endothelial damage and/or
apoptosis are useful surrogate markers in assessing response to this treatment regimen in
these patients.

OUTLINE: This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice
weekly for 4 weeks. Treatment continues in the absence of disease progression or
unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until
the maximum target-inhibiting dose (MTID) is determined. The MTID is defined as the dose at
which patients experience no greater than grade 1 toxicity. Patients are followed every 3
months.

PROJECTED ACCRUAL: Approximately 20-30 patients will be accrued for this study.

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed solid tumors not amenable to
conventional therapy At least 2 distinct lesions of metastatic or primary tumor of at
least 1-2 cm OR Single lesion if large enough for both biopsy and MRI flow studies No
brain metastases or primary brain tumors

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.